Search Results

Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.

Mustang Bio, Inc. today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,130,000 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.41 per share.

Mustang Bio, Inc. announced the pricing of a public offering of an aggregate of 16,877,638 shares of its common stock, Series A-1 warrants to purchase up to 16,877,638 shares of common stock, Series A-2 warrants to purchase up to 16,877,638 shares of common stock and Series A-3 warrants to purchase up to 16,877,638 shares of common stock, at a combined public offering price of $0.237 per share and accompanying warrants.

Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced its expansion into autoimmune diseases with MB-106, a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy.